美股市場個股詳情
IKT Inhibikase Therapeutics
- 1.3700
- +0.0300+2.24%
交易中 05/03 14:44 (美東)
887.33萬總市值-383市盈率TTM
1.4921最高價1.3500最低價3.65萬股成交量1.3800今開1.3400昨收5.12萬成交額0.66%換手率虧損市盈率(靜)647.68萬總股本4.351252周最高0.81市淨率763.59萬流通值0.790052周最低--股息TTM557.37萬流通股70.8000歷史最高--股息率TTM10.60%振幅0.7900歷史最低1.4020平均價1股每手
Inhibikase Therapeutics股票討論區
登錄發表評論
Update
$Inhibikase Therapeutics(IKT.US$ Inhibikase Reports Preliminary Outcomes Of Pre-NDA Meeting With FDA On Pathway For Approval For IkT-001Pro In Blood And Gastrointestinal Cancers; Says Given Specific Guidance On Manufacturing Requirements Necessary To Complete NDA
1
1
Like!
$Inhibikase Therapeutics(IKT.US$ Inhibikase Therapeutics beat estimated earnings by 27.73%, reporting an EPS of $-0.86 versus an estimate of $-1.19.
Revenue was up $72 thousand from the same period last year.
Revenue was up $72 thousand from the same period last year.
1
$Inhibikase Therapeutics(IKT.US$ we've had our fast track and now waiting for updated news as to results. 10 steps ahead of $Genprex(GNPX.US$ who are having their FDA fast track pump now.
iKT pulled back and some after the FDA fast track news. Next step here might just be the BIG one as well as a ream of catalysts in toe.
Time for GNPX to bank and throw some into wealth creator IKT 😉
iKT pulled back and some after the FDA fast track news. Next step here might just be the BIG one as well as a ream of catalysts in toe.
Time for GNPX to bank and throw some into wealth creator IKT 😉
1
暫無評論
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅
Trytosaveabit樓主 : Inhibikase 總裁兼首席執行官 Milton Werner 博士表示，當我們開始建立需要批准的第一個 NDA 套件的過程時，我們對與 FDA 進行的討論感到滿意。「我們的生物等效研究已向 FDA 呈交，並且我們獲得了有關完成 NDA 所需的製造要求的具體指導。FDA 承認合適的批准途徑似乎是 505 (b) (2)，我們計劃研究所有 11 種適當的適應症，包括在兒童中使用該藥物。由於我們與潛在商業化合作夥伴討論這些細節，並進行 NDA 提交所需的工作，我們還有重要工作，」Werner 博士表示。